Resumen

ARREAGA, Carlos. D-dimer and other biomarkers associated with lethality in patients with COVID-19. Vive Rev. Salud [online]. 2022, vol.5, n.14, pp.535-551.  Epub 30-Ago-2022. ISSN 2664-3243.  https://doi.org/10.33996/revistavive.v5i14.167.

COVID-19, initially with unknown pathophysiological picture; led to a high mortality rate. Biomarkers became valuable for prognosis; identifying the severity and mortality of the disease in hospitalized patients. According to the pathophysiology, patients in critical condition due to COVID 19 suffer from hypercoagulability; determined by complementary laboratory tests that show increased D-Dimer, decreased platelet and lymphocyte counts; these changes are part of the genesis of multiorgan failure becoming a risk factor for mortality. The methodology used was a systematic review based on PRISMA guidelines, compiling 2107 studies, of which 12 were selected according to inclusion and exclusion criteria. The search platforms were PubMed, Scopus, WoS, Science direct. The review was based on current knowledge of biomarkers used associated with mortality in patients with COVID-19. From the 12 studies, 2525 SARS-CoV2 positive patients were registered. The results showed that the age of the patients ranged from 16 to 75 years, and their mortality averaged from 0 to 28.2%. This review concludes that increased D-dimer is associated with severe complications or mortality in patients with COVID-19; therefore, it can be used as a predictive biomarker and suggests that hematological laboratory tests contribute to identify COVID-19 infected patients in risk groups, which is essential in the clinical setting and therapeutic management.

Palabras clave : nCoV-19; Biomarkers; Mortality; Predictive value of tests; Fibrin D fragment.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )